We are focused on the development and commercialization of innovative specialty therapies for patients with life-threatening infectious diseases and other difficult-to-treat conditions, and we believe that with the right people, the right knowledge and the right drugs, we can make a difference in patients’ lives and lead to Positive Patient Stories®.
Slide to view more
*Paratek has global rights to NUZYRA® with the exception of the greater China region where Paratek has entered into a collaboration agreement with Zai Lab (Shanghai) Co., Ltd.
NUZYRA® (omadacycline), approved by the FDA, is a once-daily oral and intravenous antibiotic for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. See full prescribing information here.
Paratek remains committed to the further study of NUZYRA® in additional areas on unmet medical need. For a full list of ongoing clinical studies, please visit clinicaltrials.gov.
Under a broad-based Project BioShield contract with Biomedical Advanced Research and Development Authority, or BARDA, which is a part of the United States Department of Health and Human Services and the Office of the Assistant Secretary for Preparedness and Response, NUZYRA® is being studied against anthrax, a pathogenic agent that potentially causes an infectious disease of public health and biodefense importance.
Paratek owns world-wide rights to omadacycline. Paratek has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., to support the development and commercialization of omadacycline for patients in Greater China.
Learn more about NUZYRA® including important safety information, and see our patent portfolio.
XHANCE® (fluticasone propionate) XHANCE is a prescription nasal spray approved by the U.S. FDA for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.
XHANCE® uses a unique Exhalation Delivery System (EDS). XHANCE® is designed to transport fluticasone deep into the nasal cavity, targeting the site of inflammation. See full prescribing information here and instructions for use here .
Paratek remains committed to the further study of XHANCE® in additional areas of unmet medical need. For a full list of ongoing clinical studies, please visit clinicaltrials.gov.
The FDA approved SEYSARA® (sarecycline) in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. SEYSARA® is marketed by Almirall, LLC in the U.S. For complete prescribing information, including the Warnings and Precautions, please visit here.
Almirall, LLC owns the rights to sarecycline and is currently exploring partnership opportunities to develop and approve sarecycline in appropriate markets. For information, please visit here (Contact Us | Almirall).
Interested in partnership opportunities? Please contact us at bd@paratekpharma.com and you will be directed to our Business Development Team
Learn more about prescribing NUZYRA® to your patients.
DownloadLearn more about prescribing XHANCE® to your patients.
Read More
